Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF)

Key Points

• Dapagliflozin and empagliflozin showed potential benefits in patients with heart failure with preserved ejection fraction, enhancing treatment options.
• Clinical evidence indicates significant improvements in heart failure management, notably through the use of these medications.
• Guideline recommendations are based on recent advancements in treatments for acute and chronic heart failure, emphasizing the value of SGLT2 inhibitors.
• This approach may enable better patient outcomes in managing heart failure, particularly in those with preserved ejection fraction.